基于MVA的MUC1癌症疫苗与TLR9配体Litenimod(Li28)序贯给药可增强局部抗肿瘤免疫防御
该研究在临床前肿瘤模型中评估TG4010的研究版本MVATG9931与B型TLR9配体Litenimod(Li28)序贯联合的效果。结果显示,亚optimal剂量MVATG9931与Li28联合较单用任一治疗明显提高皮下RMA-MUC1肿瘤模型生存率,且该保护依赖MUC1新合成、Li28于MVATG9931后数小时同部位给药、至少两个疫苗接种周期及接种部位附近植入MUC1阳性肿瘤细胞。
要点
- 亚optimal剂量MVATG9931与Li28序贯联合较单用MVATG9931或Li28明显提高皮下RMA-MUC1肿瘤模型生存率
- 保护要求包括MUC1新合成、Li28在MVATG9931后数小时同部位给药、至少两个疫苗接种周期
- 氯膦酸盐脂质体清除注射部位巨噬细胞可降低局部IL-18水平并显著降低生存率
核心结论
- MVATG9931与Li28序贯给药可增强局部固有和适应性抗肿瘤免疫防御,作者据此提出该序贯联合治疗可考虑瘤内递送。
研究设计与样本
- 临床前肿瘤模型研究,使用TG4010的研究版本MVATG9931与B型TLR9配体Litenimod(Li28),在皮下RMA-MUC1肿瘤模型及相应免疫学检测中评估联合治疗。
主要发现
- 亚optimal剂量MVATG9931与Li28联合较单用MVATG9931或Li28明显提高皮下RMA-MUC1肿瘤模型生存率。
- 皮下注射MVATG9931可实现短暂局部基因表达,并诱导MCP-1、RANTES、M-CSF、IL-15/IL-15R和IP-10局部聚集。
- 重复注射后注射部位周围聚集CD4+和CD8+ T淋巴细胞、B淋巴细胞、NK细胞、pDCs、中性粒细胞和巨噬细胞,局部RANTES水平保持较高。
- 在该环境中延迟注射Li28进一步增加巨噬细胞聚集、IL-18和IL-1 beta分泌,并提高活化CD69+ NK细胞百分比。
- 联合治疗增加引流淋巴结中活化CD86+ DC数量,并提高注射部位KLRG1+CD127-CD8+ T细胞百分比;氯膦酸盐脂质体清除注射部位周围巨噬细胞降低局部IL-18水平并显著降低生存率。
关键数值与推荐
- 保护要求为:MUC1新合成;Li28在MVATG9931后数小时于同一部位递送;至少两个疫苗接种周期;MUC1阳性肿瘤细胞植入接种部位附近。
临床怎么用
- 作者认为该序贯联合治疗可考虑瘤内递送。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TG4010 is an immunotherapeutic vaccine based on Modified Vaccinia virus Ankara (MVA) encoding the human tumor-associated antigen MUC1 and human IL-2. In combination with first-line standard of care chemotherapy in advanced metastatic non-small-cell lung cancer (NSCLC), repeated subcutaneous injection of TG4010 improved progression-free survival in phase 2b clinical trials. In preclinical tumor models, MVATG9931, the research version of TG4010, conferred antigen-specific responses against the weak antigen human MUC1. The combination of a suboptimal dose of MVATG9931 and the type B TLR9 ligand Litenimod (Li28) markedly increased survival in a subcutaneous RMA-MUC1 tumor model compared to the treatment with MVATG9931 or Li28 alone. The requirements for this protection were (i) de novo synthesis of MUC1, (ii) Li28 delivered several hours after MVATG9931 at the same site, (iii) at least two vaccination cycles, and (iv) implantation of MUC1-positive tumor cells in the vicinity to the vaccination site. Subcutaneously injected MVATG9931 allowed transient local gene expression and induced the local accumulation of MCP-1, RANTES, M-CSF, IL-15/IL-15R and IP-10. After repeated injection, CD4+ and CD8+ T lymphocytes, B lymphocytes, NK cells, pDCs, neutrophils, and macrophages accumulated around the injection site, local RANTES levels remained high. Delayed injection of Li28 into this environment, led to further accumulation of macrophages, the secretion of IL-18 and IL-1 beta, and an increase of the percentage of activated CD69+ NK cell. Combination treatment augmented the number of activated CD86+ DCs in the draining lymph nodes and increased the percentage of KLRG1+ CD127-CD8+ T cells at the injection site. In vivo depletion of macrophages around the injection site by Clodronate liposomes reduced local IL-18 levels and diminished survival rates significantly. Thus, sequential administration of MVATG9931 and Li28 improves local innate and adaptive immune defense against tumors, arguing for intratumoral delivery of this peculiar sequential combination therapy.
引用
- Schaedler E, Remy-Ziller C, Hortelano J, et al. Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors. Vaccine. 2016. PMID: 28012777. doi:10.1016/j.vaccine.2016.12.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。